-
1
-
-
79960320200
-
-
Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
-
Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2011.
-
(2011)
Tradjenta [package insert].
-
-
-
2
-
-
79955022470
-
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
-
Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 542-550.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 542-550
-
-
Forst, T.1
Uhlig-Laske, B.2
Ring, A.3
Ritzhaupt, A.4
Graefe-Mody, U.5
Dugi, K.A.6
-
3
-
-
77954798308
-
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
-
Sarashina A, Sesoko S, Nakashima M et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010; 32: 1188-1204.
-
(2010)
Clin Ther
, vol.32
, pp. 1188-1204
-
-
Sarashina, A.1
Sesoko, S.2
Nakashima, M.3
-
4
-
-
77950197593
-
The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
-
Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-678.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 667-678
-
-
Blech, S.1
Ludwig-Schwellinger, E.2
Grafe-Mody, E.U.3
Withopf, B.4
Wagner, K.5
-
5
-
-
84878639052
-
Efficacy and safety of 3 doses of BI1356 (Linagliptin) in type 2 diabetes patients.
-
Boehringer Ingelheim Pharmaceuticals. In: Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 16 June 2011.
-
Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of 3 doses of BI1356 (Linagliptin) in type 2 diabetes patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 16 June 2011.
-
ClinicalTrials.gov [Internet].
-
-
-
6
-
-
84878656966
-
Japanese P III vs voglibose and placebo.
-
Boehringer Ingelheim Pharmaceuticals. In: Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 29 September 2011.
-
Boehringer Ingelheim Pharmaceuticals. Japanese P III vs voglibose and placebo. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 29 September 2011.
-
ClinicalTrials.gov [Internet].
-
-
-
7
-
-
84878633339
-
Safety and efficacy of linagliptin (BI 1356) plus metformin in type 2 diabetes, factorial design.
-
Boehringer Ingelheim Pharmaceuticals. Bethesda, MD: National Library of Medicine (US). 2000. Available from URL:. Accessed 29 September 2011.
-
Boehringer Ingelheim Pharmaceuticals. Safety and efficacy of linagliptin (BI 1356) plus metformin in type 2 diabetes, factorial design. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000. Available from URL:. Accessed 29 September 2011.
-
ClinicalTrials.gov [Internet].
-
-
-
9
-
-
78851472527
-
Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
-
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-267.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 258-267
-
-
Del Prato, S.1
Barnett, A.H.2
Huisman, H.3
Neubacher, D.4
Woerle, H.J.5
Dugi, K.A.6
-
10
-
-
79953044464
-
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
-
Forst T, Uhlig-Laske B, Ring A et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27: 1409-1419.
-
(2010)
Diabet Med
, vol.27
, pp. 1409-1419
-
-
Forst, T.1
Uhlig-Laske, B.2
Ring, A.3
-
11
-
-
79953174825
-
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
-
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-661.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 653-661
-
-
Gomis, R.1
Espadero, R.M.2
Jones, R.3
Woerle, H.J.4
Dugi, K.A.5
-
12
-
-
80053072352
-
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
-
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
-
(2011)
Diabet Med
, vol.28
, pp. 1352-1361
-
-
Owens, D.R.1
Swallow, R.2
Dugi, K.A.3
Woerle, H.J.4
-
13
-
-
78649691630
-
Safety and efficacy of linagliptin as add-on therapy to met formin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
-
Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to met formin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 65-74
-
-
Taskinen, M.R.1
Rosenstock, J.2
Tamminen, I.3
-
14
-
-
57349160286
-
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
-
Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
-
(2009)
Diabetologia
, vol.52
, pp. 17-30
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
15
-
-
70049099036
-
Assessing risk of bias in included studies.
-
Higgins J, Green S eds. Chichester, UK: John Wiley & Sons Ltd
-
Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. In: Higgins J, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, UK: John Wiley & Sons Ltd, 2011.
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series.
-
-
Higgins, J.1
Altman, D.2
Sterne, J.3
-
16
-
-
85100415918
-
-
Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from URL:. Accessed 20 June 2011.
-
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from URL:. Accessed 20 June 2011.
-
-
-
Higgins, J.1
Green, S.2
-
17
-
-
68549101842
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
-
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
-
(2009)
BMJ
, vol.339
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
-
19
-
-
84878629649
-
-
Efficacy and safety of linagliptin in patients with type 2 diabetes and poor glycemic control (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. -
-
Del Prato S, Taskinen M, Owens D et al. Efficacy and safety of linagliptin in patients with type 2 diabetes and poor glycemic control (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 1067-p.
-
-
-
Del Prato, S.1
Taskinen, M.2
Owens, D.3
-
20
-
-
79956326006
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
-
Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
-
21
-
-
84857029848
-
Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.
-
Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228-233.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 228-233
-
-
Esposito, K.1
Chiodini, P.2
Bellastella, G.3
Maiorino, M.I.4
Giugliano, D.5
-
22
-
-
84878654356
-
-
The DPP-4 inhibitor linaglitpin restores β-cell function and survival in human isolated islets (Abstract). Poster presented at: American Diabetes Association, 70th Scientific Sessions; 25-29 June 2010, Orlando, FL 1742-P.
-
Shah P, Schumann DM, Ardestani A, et al. The DPP-4 inhibitor linaglitpin restores β-cell function and survival in human isolated islets (Abstract). Poster presented at: American Diabetes Association, 70th Scientific Sessions; 25-29 June 2010, Orlando, FL 1742-P.
-
-
-
Shah, P.1
Schumann, D.M.2
Ardestani, A.3
-
24
-
-
38949128333
-
-
Whitehouse Station, NJ: Merck & Co., Inc.
-
Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2011.
-
(2011)
Januvia [package insert].
-
-
-
25
-
-
74549198914
-
-
Princeton, NJ: Bristol-Myers Squibb
-
Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2011.
-
(2011)
Onglyza [package insert].
-
-
-
26
-
-
79951701438
-
Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
-
Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34: 369-374.
-
(2011)
Diabetes Care
, vol.34
, pp. 369-374
-
-
Willemen, M.J.1
Mantel-Teeuwisse, A.K.2
Straus, S.M.3
Meyboom, R.H.4
Egberts, T.C.5
Leufkens, H.G.6
-
27
-
-
84878643478
-
-
Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 39-LB.
-
Gallwitz B, Uhlig-Laske B, Bhattacharaya S, Patel S, Woerle HJ. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 39-LB.
-
-
-
Gallwitz, B.1
Uhlig-Laske, B.2
Bhattacharaya, S.3
Patel, S.4
Woerle, H.J.5
-
28
-
-
84878666336
-
-
CV risk with linagliptin in patients with type 2 diabetes: a prespecified, prospective, and adjuicated meta-analysis from a large phase III program (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 0030-LB.
-
Johansen OE, Neubacher D, Von Eynatten M, Patel S, Woerle HJ. CV risk with linagliptin in patients with type 2 diabetes: a prespecified, prospective, and adjuicated meta-analysis from a large phase III program (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 0030-LB.
-
-
-
Johansen, O.E.1
Neubacher, D.2
Von Eynatten, M.3
Patel, S.4
Woerle, H.J.5
-
29
-
-
84878648020
-
-
Dipepidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? (Abstract). Poster presented at: European Association for the Study of Diabetes 2011 Meeting; 16 September 2011; Lisbon, Portugal. 244.
-
Lamanna C, Monami M, Bartoli N, et al. Dipepidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? (Abstract). Poster presented at: European Association for the Study of Diabetes 2011 Meeting; 16 September 2011; Lisbon, Portugal. 244.
-
-
-
Lamanna, C.1
Monami, M.2
Bartoli, N.3
-
30
-
-
84878660610
-
-
Rationale and design of the CAROLINA Trial: an active comparator CARdOvascular outcome study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 1103-P.
-
Rosenstock J, Marx N, Kahn SE, et al. Rationale and design of the CAROLINA Trial: an active comparator CARdOvascular outcome study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 1103-P.
-
-
-
Rosenstock, J.1
Marx, N.2
Kahn, S.E.3
-
31
-
-
79955728359
-
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
-
Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27: 362-372.
-
(2011)
Diabetes Metab Res Rev
, vol.27
, pp. 362-372
-
-
Monami, M.1
Cremasco, F.2
Lamanna, C.3
Marchionni, N.4
Mannucci, E.5
-
32
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
-
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
Elashoff, R.4
Butler, P.C.5
-
33
-
-
0043198131
-
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
-
Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928.
-
(2003)
JAMA
, vol.290
, pp. 921-928
-
-
Als-Nielsen, B.1
Chen, W.2
Gluud, C.3
Kjaergard, L.L.4
-
34
-
-
0038439242
-
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
-
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170.
-
(2003)
BMJ
, vol.326
, pp. 1167-1170
-
-
Lexchin, J.1
Bero, L.A.2
Djulbegovic, B.3
Clark, O.4
|